View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 30, 2015updated 25 Oct 2021 10:49am

Mylan offers to acquire Perrigo for $34bn

US-based Mylan has increased its offer to acquire all of outstanding shares of Ireland-based over-the-counter (OTC) and nutritional products maker Perrigo.

Perrigo .jpg” alt=”Perrigo ” width=”247″ height=”156″ />

US-based Mylan has increased its offer to acquire all of outstanding shares of Ireland-based over-the-counter (OTC) and nutritional products maker Perrigo .

It will pay $75.00 per share in cash, with 2.3 Mylan ordinary shares for each ordinary Perrigo share

The company noted that based on its closing stock price of $68.36 on April, the first day of market reaction to the initial proposal, the value of the new offer is $232.23 per Perrigo share or $34bn.

Mylan executive chairman Robert Coury said: “With this enhanced offer, I look forward to meeting with Joe Papa and his team to finalise the implementation of this truly compelling combination, which is a win-win for both Mylan and Perrigo shareholders and all other stakeholders.

Perrigo has again rejected the increased acquisition offer, claiming that Mylan continues to propose a price lower than the previously rejected offer.”

“Previously, Mylan filed for US anti-trust clearance, made a ‘hell or high water’ commitment with respect to obtaining this clearance and committed to a timetable for closing. We have also secured firm committed financing for our offer.”

However, Perrigo has again rejected the increased acquisition offer, claiming that Mylan continues to propose a price lower than the previously rejected offer.

Earlier this month, Mylan made an offer to acquire Perrigo for around $29bn in a cash and stock deal.

Morgan Stanley & Co acting through its affiliate, Morgan Stanley & Co. International plc, and JP Morgan Securities are acting as financial advisors to Perrigo .

Last week, Israel-based Teva Pharmaceutical Industries made an offer of around $40bn to acquire Mylan, but it was rejected by the US drugmaker.


Image: Photograph of the exterior of Perrigo ‘s Eastern Avenue Office. Photo: courtesy of Perrigo Company.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology